Mode
Text Size
Log in / Sign up

Vancomycin Tied to Rare Immune Hemolytic Anemia in Case ReviewVancomycin use can cause a rare blood cell reaction

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Suspect immune hemolytic anemia in patients on vancomycin, including bone cement use, though the reaction is rare.

A 64-year-old woman developed immune hemolytic anemia after receiving vancomycin, according to a case report that also reviewed five previously published cases. The findings add to evidence that the antibiotic can trigger a rare blood disorder.

Serological tests and drug antibody titers supported the diagnosis in the new case. The authors note that the reaction is uncommon but can occur with systemic vancomycin and with vancomycin-loaded bone cement.

The review of five earlier cases showed similar patterns, though details on timing, treatment, and outcomes were limited. No information was available on follow-up, discontinuations, or serious adverse events beyond the hemolytic anemia itself.

Clinicians should maintain a high index of suspicion for hemolysis when patients receive vancomycin, including in orthopedic procedures using antibiotic cement. Early recognition may prevent severe complications.

The small sample size and reliance on case reports limit broader conclusions. The association is reported, but causality is not proven, and the condition remains rare.

How this fits prior evidence

Prior coverage has focused on vancomycin efficacy and infection prevention, including intrawound vancomycin in spinal fusion (no reduction in surgical site infection), MRSA nares PCR in ICU CAP (no reduction in vancomycin duration or mortality), oral vancomycin prophylaxis in HSCT (reduced Clostridium difficile incidence), intrawound antibiotic powder in pelvic and lower-limb fractures (37% reduction in fracture-related infection odds), and intraosseous vancomycin in primary TKA (increased local tissue concentration and reduced infection rates). This case report and literature review addresses a different safety signal, immune hemolytic anemia, which is not covered in those prior items.

Imagine taking a common antibiotic to fight an infection, only to have your body start attacking its own red blood cells. This is what happens in a condition called immune hemolytic anemia. While it is rare, it can be serious for patients receiving vancomycin, a medication often used for various infections.

One case report and a review of five other cases highlighted this specific risk. The reports showed that the drug can trigger the immune system to destroy blood cells. Doctors are now looking closer at these cases to ensure they can spot the signs early, especially when the drug is used in specific ways like in bone cement.

Because the total number of reported cases is very small, we do not have a lot of data on how often this happens. However, the evidence shows that doctors should stay alert. If a patient on vancomycin shows signs of blood cell issues, medical teams need to act quickly to manage the reaction.

What this means for you:
Vancomycin can cause a rare immune reaction where the body destroys its own red blood cells.

Common questions

What is immune hemolytic anemia?

This is a condition where your immune system mistakenly attacks and destroys your own red blood cells. In the cases reported, this reaction was triggered by the antibiotic vancomycin. When red blood cells are destroyed too quickly, it can cause serious health issues for the patient.

Is it common to have this reaction to vancomycin?

No, this condition is rare. The report included one new case and five previously reported cases. Because the number of cases is so small, it is not a common side effect, but doctors are advised to remain alert for it when they prescribe the medication.

When should doctors be most concerned about this?

Doctors should maintain a high suspicion for this blood cell issue in any patient taking vancomycin. This includes cases where the drug is used in bone cement. If a patient shows signs of hemolysis, the medical team needs to identify the cause quickly.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Drug-induced immune hemolytic anemia (DIIHA) is a rare but potentially life-threatening adverse drug reaction. Although more than 150 drugs have been reported to induce DIIHA, vancomycin, a glycopeptide antibiotic widely used in clinical practice, is rarely associated with hemolysis, making it prone to underdiagnosis or misdiagnosis. This article reports a case of vancomycin-induced DIIHA in a 64-year-old female patient after right revision knee arthroplasty (RKA). This study investigated the serological tests associated with vancomycin and tracks drug antibody titers through longitudinal monitoring during clinical diagnosis and treatment. Additionally, a literature review identified and summarized five previously reported cases of vancomycin-induced immune hemolytic anemia. Clinicians should maintain a high index of suspicion for hemolysis associated with vancomycin, including its use in bone cement. Early recognition, prompt withdrawal of the offending agent, and transfusion support are imperative for improving patient outcomes with DIIHA.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.